Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice

[1]  W. Lim,et al.  Corticosteroids as adjunctive therapy in the treatment of influenza. , 2019, The Cochrane database of systematic reviews.

[2]  A. Tam,et al.  Efficacy of Clarithromycin‐Naproxen‐Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open‐label Randomized, Controlled, Phase IIb/III Trial , 2017, Chest.

[3]  M. Lipsitch,et al.  Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study. , 2017, The Lancet. Infectious diseases.

[4]  H. Kido,et al.  IL-1β is a key cytokine that induces trypsin upregulation in the influenza virus–cytokine–trypsin cycle , 2016, Archives of Virology.

[5]  K. To,et al.  Mycophenolic acid, an immunomodulator, has potent and broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian influenza viruses affecting humans. , 2016, The Journal of general virology.

[6]  H. Zaraket,et al.  Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections , 2016, Front. Microbiol..

[7]  K. To,et al.  Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial. , 2016, The Lancet. Infectious diseases.

[8]  J. Mejía-Aranguré,et al.  TNF, IL6, and IL1B Polymorphisms Are Associated with Severe Influenza A (H1N1) Virus Infection in the Mexican Population , 2015, PloS one.

[9]  A. Fernández-Sesma,et al.  Modulating the Innate Immune Response to Influenza A Virus: Potential Therapeutic Use of Anti-Inflammatory Drugs , 2015, Front. Immunol..

[10]  Kwang Seok Kim,et al.  Induction of interleukin‐1 beta (IL‐1β) is a critical component of lung inflammation during influenza A (H1N1) virus infection , 2015, Journal of medical virology.

[11]  G. Roh,et al.  Clarithromycin Attenuates Radiation-Induced Lung Injury in Mice , 2015, PloS one.

[12]  K. To,et al.  Avian Influenza A H7N9 Virus Induces Severe Pneumonia in Mice without Prior Adaptation and Responds to a Combination of Zanamivir and COX-2 Inhibitor , 2014, PloS one.

[13]  F. Hayden,et al.  Antiviral combinations for severe influenza , 2014, The Lancet Infectious Diseases.

[14]  H. Kubo,et al.  Additional treatment with clarithromycin reduces fever duration in patients with influenza. , 2014, Respiratory investigation.

[15]  Gokhan Metan,et al.  Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. , 2014, The Lancet. Respiratory medicine.

[16]  Akiko Iwasaki,et al.  Innate immunity to influenza virus infection , 2014, Nature Reviews Immunology.

[17]  K. To,et al.  Unique reassortant of influenza A(H7N9) virus associated with severe disease emerging in Hong Kong , 2014, Journal of Infection.

[18]  K. To,et al.  Mice A ( H 1 N 1 ) pdm 09 Virus Infection in BALB / c Responses against Influenza Expedites and Augments Humoral Immune Combination with Influenza Vaccine Toll-Like Receptor 7 Agonist Imiquimod in , 2014 .

[19]  S. Ōmura,et al.  Leucomycin A3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression , 2014, The Journal of Antibiotics.

[20]  Shu-Min Lin,et al.  Adjuvant Treatment With a Mammalian Target of Rapamycin Inhibitor, Sirolimus, and Steroids Improves Outcomes in Patients With Severe H1N1 Pneumonia and Acute Respiratory Failure* , 2014, Critical care medicine.

[21]  K. To,et al.  Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus , 2013, Journal of Infection.

[22]  C. D. Del Negro,et al.  Flufenamic acid as an ion channel modulator. , 2013, Pharmacology & therapeutics.

[23]  Wenjun Song,et al.  Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome , 2013, The Lancet.

[24]  C. Di Primo,et al.  Structure-Based Discovery of the Novel Antiviral Properties of Naproxen against the Nucleoprotein of Influenza A Virus , 2013, Antimicrobial Agents and Chemotherapy.

[25]  Semicyuc,et al.  Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia , 2013, Intensive Care Medicine.

[26]  T. Marrie,et al.  Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Herman Tse,et al.  Two Years after Pandemic Influenza A/2009/H1N1: What Have We Learned? , 2012, Clinical Microbiology Reviews.

[28]  K. Preissner,et al.  Disruption of platelet-derived chemokine heteromers prevents neutrophil extravasation in acute lung injury. , 2012, American journal of respiratory and critical care medicine.

[29]  Yoko Ito,et al.  Innate Immune Response of Human Alveolar Macrophages during Influenza A Infection , 2012, PloS one.

[30]  D. Smee,et al.  Efficacy of Combined Therapy with Amantadine, Oseltamivir, and Ribavirin In Vivo against Susceptible and Amantadine-Resistant Influenza A Viruses , 2012, PloS one.

[31]  Min Soo Han,et al.  Triple-Combination Antiviral Drug for Pandemic H1N1 Influenza Virus Infection in Critically Ill Patients on Mechanical Ventilation , 2011, Antimicrobial Agents and Chemotherapy.

[32]  S. Koizumi,et al.  Nonsteroidal Anti-Inflammatory Drug Flufenamic Acid Is a Potent Activator of AMP-Activated Protein Kinase , 2011, Journal of Pharmacology and Experimental Therapeutics.

[33]  Samson S. Y. Wong,et al.  Delayed Clearance of Viral Load and Marked Cytokine Activation in Severe Cases of Pandemic H1N1 2009 Influenza Virus Infection , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  D. Smee,et al.  Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro , 2010, PloS one.

[35]  Samson S. Y. Wong,et al.  Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus , 2008, Proceedings of the National Academy of Sciences.

[36]  D. Miyamoto,et al.  Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells. , 2008, Biological & pharmaceutical bulletin.

[37]  D. Gemsa,et al.  Defense against influenza A virus infection: essential role of the chemokine system. , 2001, Immunobiology.

[38]  A. Inglot.  Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. , 1969, The Journal of general virology.